Bicara Therapeutics/$BCAX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Bicara Therapeutics
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
- Ticker
- $BCAX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 103
- Headquarters
- Boston, United States
- Website
- www.bicara.com
BCAX Metrics
BasicAdvanced
$1.2B
-
-$3.11
-0.82
-
Price and volume
Market cap
$1.2B
Beta
-0.82
52-week high
$30.99
52-week low
$13.70
Average daily volume
789K
Financial strength
Current ratio
11.589
Quick ratio
11.438
Total debt to equity
0.002
Profitability
EBITDA (TTM)
-201.834
Effective tax rate (TTM)
-0.11%
Management effectiveness
Return on assets (TTM)
-26.14%
Return on equity (TTM)
-41.01%
Valuation
Price to book
2.48
Price to tangible book (TTM)
2.48
Price to free cash flow (TTM)
-7.759
Free cash flow yield (TTM)
-12.89%
Free cash flow per share (TTM)
-2.27
Growth
Earnings per share change (TTM)
32.30%
What the Analysts think about BCAX
Analyst ratings (Buy, Hold, Sell) for Bicara Therapeutics stock.
Analyst projections of the future price of Bicara Therapeutics stock.
Bulls say / Bears say
In a 28-patient HPV-negative subgroup, ficerafusp alfa plus pembrolizumab produced a 54% confirmed response rate, including 21% complete responses. Median response duration was 21.7 months, suggesting some patients may benefit for a long time. (Journal of Clinical Oncology)
Longer follow-up showed an estimated three-year survival rate of 31% in the 1,500mg weekly cohort, which Bicara said was about twice the rate in a retrospective pembrolizumab comparison. If confirmed in the pivotal trial, this could support a meaningful treatment benefit. (GlobeNewswire)
Bicara reported $497.3 million in cash and marketable securities at the end of June 2026, with a projected runway into the first half of 2029. That gives it funding to advance its pivotal study and other development work without an immediate need to raise more capital. (GlobeNewswire)
The encouraging response and survival figures come from small early-stage cohorts, while the three-year comparison uses historical rather than randomised control data. The pivotal study still needs to show that the benefit holds up against pembrolizumab in a controlled trial. (Journal of Clinical Oncology, GlobeNewswire)
Treatment burden could limit use: 45% of patients in the published cohort had a severe treatment-related side effect, 48% had treatment interruptions, and 12% stopped ficerafusp alfa because of side effects. These rates will need to be weighed against the treatment's benefit in larger studies. (Journal of Clinical Oncology)
The pivotal trial is expected to be substantially enrolled only by the end of 2026, with an interim readout planned for mid-2027. That leaves investors exposed to further execution risk and a long wait before randomised evidence can validate the early results. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2026.
BCAX Financial Performance
Revenues and expenses
BCAX Earnings Performance
Company profitability
Upcoming events
No upcoming events
BCAX News
AllArticlesVideos
Funds containing BCAX
Fund name | Fund size | $BCAX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.08% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.08% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
iShares MSCI World Small Cap£WLDS | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.